Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients.

CONCLUSION: The status of RAD50 promoter's methylation inversely correlates with the expression level of RAD50. While RAD50 is overexpressed in breast cancer patients and thus makes tumor resistant against many anti-cancer drugs.
PMID: 33038913 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - October 9, 2020 Category: Cancer & Oncology Authors: Karamat U, Ejaz S Tags: Curr Cancer Drug Targets Source Type: research